BeiGene, Ltd. (BGNE) Stock Competitors & Peer Comparison
See (BGNE) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| NVO | $42.79 | +1.42% | 190.1B | 10.04 | $4.26 | +4.27% |
| VRTX | $435.49 | -2.31% | 110.5B | 25.88 | $16.83 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $601.58 | -2.37% | 62B | 14.68 | $40.99 | +0.59% |
| ARGX | $862.18 | -2.47% | 53.4B | 38.30 | $22.51 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $291.38 | -2.12% | 38.9B | 73.40 | $3.97 | N/A |
| RVMD | $144.19 | -3.58% | 30.7B | -20.34 | -$7.09 | N/A |
| RPRX | $54.52 | -2.00% | 23.5B | 28.69 | $1.90 | +1.64% |
Stock Comparison
BGNE vs NVO Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, NVO has a market cap of 190.1B. Regarding current trading prices, BGNE is priced at $184.71, while NVO trades at $42.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas NVO's P/E ratio is 10.04. In terms of profitability, BGNE's ROE is +0.12%, compared to NVO's ROE of +0.66%. Regarding short-term risk, BGNE is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check NVO's competition here
BGNE vs VRTX Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, VRTX has a market cap of 110.5B. Regarding current trading prices, BGNE is priced at $184.71, while VRTX trades at $435.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas VRTX's P/E ratio is 25.88. In terms of profitability, BGNE's ROE is +0.12%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, BGNE is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check VRTX's competition here
BGNE vs VRNA Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, BGNE is priced at $184.71, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas VRNA's P/E ratio is -102.80. In terms of profitability, BGNE's ROE is +0.12%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, BGNE is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check VRNA's competition here
BGNE vs REGN Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, REGN has a market cap of 62B. Regarding current trading prices, BGNE is priced at $184.71, while REGN trades at $601.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas REGN's P/E ratio is 14.68. In terms of profitability, BGNE's ROE is +0.12%, compared to REGN's ROE of +0.14%. Regarding short-term risk, BGNE is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check REGN's competition here
BGNE vs ARGX Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, ARGX has a market cap of 53.4B. Regarding current trading prices, BGNE is priced at $184.71, while ARGX trades at $862.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas ARGX's P/E ratio is 38.30. In terms of profitability, BGNE's ROE is +0.12%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, BGNE is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ARGX's competition here
BGNE vs SGEN Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, BGNE is priced at $184.71, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas SGEN's P/E ratio is -57.19. In terms of profitability, BGNE's ROE is +0.12%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, BGNE is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check SGEN's competition here
BGNE vs ALNY Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, ALNY has a market cap of 38.9B. Regarding current trading prices, BGNE is priced at $184.71, while ALNY trades at $291.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas ALNY's P/E ratio is 73.40. In terms of profitability, BGNE's ROE is +0.12%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, BGNE is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ALNY's competition here
BGNE vs RVMD Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, RVMD has a market cap of 30.7B. Regarding current trading prices, BGNE is priced at $184.71, while RVMD trades at $144.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas RVMD's P/E ratio is -20.34. In terms of profitability, BGNE's ROE is +0.12%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, BGNE is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check RVMD's competition here
BGNE vs RPRX Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, RPRX has a market cap of 23.5B. Regarding current trading prices, BGNE is priced at $184.71, while RPRX trades at $54.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas RPRX's P/E ratio is 28.69. In terms of profitability, BGNE's ROE is +0.12%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, BGNE is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check RPRX's competition here
BGNE vs UTHR Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, UTHR has a market cap of 23.1B. Regarding current trading prices, BGNE is priced at $184.71, while UTHR trades at $544.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas UTHR's P/E ratio is 20.11. In terms of profitability, BGNE's ROE is +0.12%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, BGNE is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check UTHR's competition here
BGNE vs BNTX Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, BNTX has a market cap of 21.8B. Regarding current trading prices, BGNE is priced at $184.71, while BNTX trades at $86.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas BNTX's P/E ratio is -14.65. In terms of profitability, BGNE's ROE is +0.12%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, BGNE is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check BNTX's competition here
BGNE vs INCY Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, INCY has a market cap of 21.1B. Regarding current trading prices, BGNE is priced at $184.71, while INCY trades at $105.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas INCY's P/E ratio is 14.89. In terms of profitability, BGNE's ROE is +0.12%, compared to INCY's ROE of +0.29%. Regarding short-term risk, BGNE is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check INCY's competition here
BGNE vs ROIV Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, ROIV has a market cap of 20.4B. Regarding current trading prices, BGNE is priced at $184.71, while ROIV trades at $28.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas ROIV's P/E ratio is -52.61. In terms of profitability, BGNE's ROE is +0.12%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, BGNE is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ROIV's competition here
BGNE vs INSM Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, INSM has a market cap of 19.9B. Regarding current trading prices, BGNE is priced at $184.71, while INSM trades at $91.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas INSM's P/E ratio is -15.95. In terms of profitability, BGNE's ROE is +0.12%, compared to INSM's ROE of -1.30%. Regarding short-term risk, BGNE is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check INSM's competition here
BGNE vs DNA-WT Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, BGNE is priced at $184.71, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, BGNE's ROE is +0.12%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, BGNE is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check DNA-WT's competition here
BGNE vs MRNA Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, MRNA has a market cap of 18.2B. Regarding current trading prices, BGNE is priced at $184.71, while MRNA trades at $46.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas MRNA's P/E ratio is -5.64. In terms of profitability, BGNE's ROE is +0.12%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, BGNE is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check MRNA's competition here
BGNE vs NBIX Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, NBIX has a market cap of 16.2B. Regarding current trading prices, BGNE is priced at $184.71, while NBIX trades at $160.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas NBIX's P/E ratio is 24.71. In terms of profitability, BGNE's ROE is +0.12%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, BGNE is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check NBIX's competition here
BGNE vs GMAB Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, GMAB has a market cap of 15B. Regarding current trading prices, BGNE is priced at $184.71, while GMAB trades at $24.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas GMAB's P/E ratio is 18.55. In terms of profitability, BGNE's ROE is +0.12%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, BGNE is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check GMAB's competition here
BGNE vs JAZZ Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, JAZZ has a market cap of 14.4B. Regarding current trading prices, BGNE is priced at $184.71, while JAZZ trades at $229.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas JAZZ's P/E ratio is 1913.58. In terms of profitability, BGNE's ROE is +0.12%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, BGNE is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check JAZZ's competition here
BGNE vs EXEL Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, EXEL has a market cap of 13.2B. Regarding current trading prices, BGNE is priced at $184.71, while EXEL trades at $52.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas EXEL's P/E ratio is 17.41. In terms of profitability, BGNE's ROE is +0.12%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, BGNE is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check EXEL's competition here
BGNE vs BBIO Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, BBIO has a market cap of 13.2B. Regarding current trading prices, BGNE is priced at $184.71, while BBIO trades at $67.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas BBIO's P/E ratio is -17.93. In terms of profitability, BGNE's ROE is +0.12%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, BGNE is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check BBIO's competition here
BGNE vs ASND Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, ASND has a market cap of 13B. Regarding current trading prices, BGNE is priced at $184.71, while ASND trades at $209.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas ASND's P/E ratio is 24.05. In terms of profitability, BGNE's ROE is +0.12%, compared to ASND's ROE of -56.42%. Regarding short-term risk, BGNE is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ASND's competition here
BGNE vs AXSM Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, AXSM has a market cap of 12.7B. Regarding current trading prices, BGNE is priced at $184.71, while AXSM trades at $246.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas AXSM's P/E ratio is -66.22. In terms of profitability, BGNE's ROE is +0.12%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, BGNE is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check AXSM's competition here
BGNE vs KRTX Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, BGNE is priced at $184.71, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas KRTX's P/E ratio is -28.09. In terms of profitability, BGNE's ROE is +0.12%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, BGNE is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check KRTX's competition here
BGNE vs IONS Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, IONS has a market cap of 12.1B. Regarding current trading prices, BGNE is priced at $184.71, while IONS trades at $73.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas IONS's P/E ratio is -36.48. In terms of profitability, BGNE's ROE is +0.12%, compared to IONS's ROE of -0.59%. Regarding short-term risk, BGNE is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check IONS's competition here
BGNE vs RNAM Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, BGNE is priced at $184.71, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas RNAM's P/E ratio is -17.39. In terms of profitability, BGNE's ROE is +0.12%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, BGNE is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check RNAM's competition here
BGNE vs MDGL Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, MDGL has a market cap of 10.9B. Regarding current trading prices, BGNE is priced at $184.71, while MDGL trades at $471.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas MDGL's P/E ratio is -34.92. In terms of profitability, BGNE's ROE is +0.12%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, BGNE is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check MDGL's competition here
BGNE vs BMRN Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, BMRN has a market cap of 10.9B. Regarding current trading prices, BGNE is priced at $184.71, while BMRN trades at $56.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas BMRN's P/E ratio is 40.41. In terms of profitability, BGNE's ROE is +0.12%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, BGNE is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check BMRN's competition here
BGNE vs SMMT Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, SMMT has a market cap of 10.1B. Regarding current trading prices, BGNE is priced at $184.71, while SMMT trades at $13.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas SMMT's P/E ratio is -8.21. In terms of profitability, BGNE's ROE is +0.12%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, BGNE is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check SMMT's competition here
BGNE vs ARWR Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, ARWR has a market cap of 10B. Regarding current trading prices, BGNE is priced at $184.71, while ARWR trades at $70.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas ARWR's P/E ratio is -31.16. In terms of profitability, BGNE's ROE is +0.12%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, BGNE is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ARWR's competition here
BGNE vs RXDX Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, BGNE is priced at $184.71, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas RXDX's P/E ratio is -56.47. In terms of profitability, BGNE's ROE is +0.12%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, BGNE is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check RXDX's competition here
BGNE vs KRYS Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, KRYS has a market cap of 9.2B. Regarding current trading prices, BGNE is priced at $184.71, while KRYS trades at $312.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas KRYS's P/E ratio is 41.77. In terms of profitability, BGNE's ROE is +0.12%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, BGNE is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check KRYS's competition here
BGNE vs NUVL Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, BGNE is priced at $184.71, while NUVL trades at $123.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas NUVL's P/E ratio is -20.35. In terms of profitability, BGNE's ROE is +0.12%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, BGNE is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check NUVL's competition here
BGNE vs IMGN Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, BGNE is priced at $184.71, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas IMGN's P/E ratio is -111.55. In terms of profitability, BGNE's ROE is +0.12%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, BGNE is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check IMGN's competition here
BGNE vs CORT Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, CORT has a market cap of 8.4B. Regarding current trading prices, BGNE is priced at $184.71, while CORT trades at $78.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas CORT's P/E ratio is 223.20. In terms of profitability, BGNE's ROE is +0.12%, compared to CORT's ROE of +0.08%. Regarding short-term risk, BGNE is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check CORT's competition here
BGNE vs HALO Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, HALO has a market cap of 8.4B. Regarding current trading prices, BGNE is priced at $184.71, while HALO trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas HALO's P/E ratio is 24.74. In terms of profitability, BGNE's ROE is +0.12%, compared to HALO's ROE of +1.26%. Regarding short-term risk, BGNE is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check HALO's competition here
BGNE vs BPMC Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, BGNE is priced at $184.71, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas BPMC's P/E ratio is -51.58. In terms of profitability, BGNE's ROE is +0.12%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, BGNE is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check BPMC's competition here
BGNE vs CYTK Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, CYTK has a market cap of 8.3B. Regarding current trading prices, BGNE is priced at $184.71, while CYTK trades at $67.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas CYTK's P/E ratio is -9.79. In terms of profitability, BGNE's ROE is +0.12%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, BGNE is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check CYTK's competition here
BGNE vs TECH Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, TECH has a market cap of 8.2B. Regarding current trading prices, BGNE is priced at $184.71, while TECH trades at $52.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas TECH's P/E ratio is 75.00. In terms of profitability, BGNE's ROE is +0.12%, compared to TECH's ROE of +0.05%. Regarding short-term risk, BGNE is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check TECH's competition here
BGNE vs CERE Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, BGNE is priced at $184.71, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas CERE's P/E ratio is -16.47. In terms of profitability, BGNE's ROE is +0.12%, compared to CERE's ROE of -0.72%. Regarding short-term risk, BGNE is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check CERE's competition here
BGNE vs MTSR Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, BGNE is priced at $184.71, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas MTSR's P/E ratio is -23.58. In terms of profitability, BGNE's ROE is +0.12%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, BGNE is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check MTSR's competition here
BGNE vs IBRX Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, IBRX has a market cap of 7.3B. Regarding current trading prices, BGNE is priced at $184.71, while IBRX trades at $6.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas IBRX's P/E ratio is -7.93. In terms of profitability, BGNE's ROE is +0.12%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, BGNE is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check IBRX's competition here
BGNE vs ALKS Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, ALKS has a market cap of 7.3B. Regarding current trading prices, BGNE is priced at $184.71, while ALKS trades at $43.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas ALKS's P/E ratio is 48.72. In terms of profitability, BGNE's ROE is +0.12%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, BGNE is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ALKS's competition here
BGNE vs TGTX Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, TGTX has a market cap of 7.1B. Regarding current trading prices, BGNE is priced at $184.71, while TGTX trades at $46.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas TGTX's P/E ratio is 16.30. In terms of profitability, BGNE's ROE is +0.12%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, BGNE is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check TGTX's competition here
BGNE vs MRUS Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, BGNE is priced at $184.71, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas MRUS's P/E ratio is -17.05. In terms of profitability, BGNE's ROE is +0.12%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, BGNE is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check MRUS's competition here
BGNE vs PTGX Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, PTGX has a market cap of 6.8B. Regarding current trading prices, BGNE is priced at $184.71, while PTGX trades at $105.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas PTGX's P/E ratio is -58.44. In terms of profitability, BGNE's ROE is +0.12%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, BGNE is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check PTGX's competition here
BGNE vs ACLX Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, BGNE is priced at $184.71, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas ACLX's P/E ratio is -28.27. In terms of profitability, BGNE's ROE is +0.12%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, BGNE is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check ACLX's competition here
BGNE vs RETA Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, BGNE is priced at $184.71, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas RETA's P/E ratio is -66.29. In terms of profitability, BGNE's ROE is +0.12%, compared to RETA's ROE of +0.47%. Regarding short-term risk, BGNE is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check RETA's competition here
BGNE vs PCVX Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, PCVX has a market cap of 6.6B. Regarding current trading prices, BGNE is priced at $184.71, while PCVX trades at $45.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas PCVX's P/E ratio is -6.74. In terms of profitability, BGNE's ROE is +0.12%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, BGNE is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check PCVX's competition here
BGNE vs LEGN Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, LEGN has a market cap of 6.4B. Regarding current trading prices, BGNE is priced at $184.71, while LEGN trades at $34.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas LEGN's P/E ratio is -25.26. In terms of profitability, BGNE's ROE is +0.12%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, BGNE is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check LEGN's competition here
BGNE vs KYMR Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, KYMR has a market cap of 6.4B. Regarding current trading prices, BGNE is priced at $184.71, while KYMR trades at $78.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas KYMR's P/E ratio is -21.85. In terms of profitability, BGNE's ROE is +0.12%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, BGNE is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check KYMR's competition here
BGNE vs ABVX Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, ABVX has a market cap of 6.4B. Regarding current trading prices, BGNE is priced at $184.71, while ABVX trades at $98.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas ABVX's P/E ratio is -18.29. In terms of profitability, BGNE's ROE is +0.12%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, BGNE is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ABVX's competition here
BGNE vs IMVT Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, IMVT has a market cap of 6.4B. Regarding current trading prices, BGNE is priced at $184.71, while IMVT trades at $31.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas IMVT's P/E ratio is -11.26. In terms of profitability, BGNE's ROE is +0.12%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, BGNE is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check IMVT's competition here
BGNE vs CNTA Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, CNTA has a market cap of 6.1B. Regarding current trading prices, BGNE is priced at $184.71, while CNTA trades at $39.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas CNTA's P/E ratio is -22.30. In terms of profitability, BGNE's ROE is +0.12%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, BGNE is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check CNTA's competition here
BGNE vs PTCT Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, PTCT has a market cap of 6.1B. Regarding current trading prices, BGNE is priced at $184.71, while PTCT trades at $73.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas PTCT's P/E ratio is -28.88. In terms of profitability, BGNE's ROE is +0.12%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, BGNE is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check PTCT's competition here
BGNE vs RYTM Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, RYTM has a market cap of 5.9B. Regarding current trading prices, BGNE is priced at $184.71, while RYTM trades at $85.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas RYTM's P/E ratio is -27.38. In terms of profitability, BGNE's ROE is +0.12%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, BGNE is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check RYTM's competition here
BGNE vs LQDA Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, LQDA has a market cap of 5.8B. Regarding current trading prices, BGNE is priced at $184.71, while LQDA trades at $65.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas LQDA's P/E ratio is 383.82. In terms of profitability, BGNE's ROE is +0.12%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, BGNE is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check LQDA's competition here
BGNE vs CDTX Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, BGNE is priced at $184.71, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas CDTX's P/E ratio is -19.77. In terms of profitability, BGNE's ROE is +0.12%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, BGNE is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check CDTX's competition here
BGNE vs ABCM Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, BGNE is priced at $184.71, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, BGNE's ROE is +0.12%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, BGNE is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check ABCM's competition here
BGNE vs ISEE Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, BGNE is priced at $184.71, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas ISEE's P/E ratio is -22.44. In terms of profitability, BGNE's ROE is +0.12%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, BGNE is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check ISEE's competition here
BGNE vs BLTE Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, BLTE has a market cap of 5.5B. Regarding current trading prices, BGNE is priced at $184.71, while BLTE trades at $136.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas BLTE's P/E ratio is -53.83. In terms of profitability, BGNE's ROE is +0.12%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, BGNE is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check BLTE's competition here
BGNE vs COGT Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, COGT has a market cap of 5.4B. Regarding current trading prices, BGNE is priced at $184.71, while COGT trades at $31.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas COGT's P/E ratio is -14.46. In terms of profitability, BGNE's ROE is +0.12%, compared to COGT's ROE of -0.83%. Regarding short-term risk, BGNE is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check COGT's competition here
BGNE vs FBIOX Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, FBIOX has a market cap of 5.3B. Regarding current trading prices, BGNE is priced at $184.71, while FBIOX trades at $24.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas FBIOX's P/E ratio is N/A. In terms of profitability, BGNE's ROE is +0.12%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, BGNE is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check FBIOX's competition here
BGNE vs SRRK Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, SRRK has a market cap of 5.3B. Regarding current trading prices, BGNE is priced at $184.71, while SRRK trades at $44.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas SRRK's P/E ratio is -12.78. In terms of profitability, BGNE's ROE is +0.12%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, BGNE is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check SRRK's competition here
BGNE vs APLS Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, BGNE is priced at $184.71, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas APLS's P/E ratio is 38.35. In terms of profitability, BGNE's ROE is +0.12%, compared to APLS's ROE of +0.40%. Regarding short-term risk, BGNE is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check APLS's competition here
BGNE vs APGE Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, APGE has a market cap of 5.1B. Regarding current trading prices, BGNE is priced at $184.71, while APGE trades at $82.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas APGE's P/E ratio is -19.10. In terms of profitability, BGNE's ROE is +0.12%, compared to APGE's ROE of -0.33%. Regarding short-term risk, BGNE is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check APGE's competition here
BGNE vs PRAX Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, PRAX has a market cap of 5.1B. Regarding current trading prices, BGNE is priced at $184.71, while PRAX trades at $240.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas PRAX's P/E ratio is -17.97. In terms of profitability, BGNE's ROE is +0.12%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, BGNE is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check PRAX's competition here
BGNE vs LGND Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, LGND has a market cap of 5B. Regarding current trading prices, BGNE is priced at $184.71, while LGND trades at $247.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas LGND's P/E ratio is 32.32. In terms of profitability, BGNE's ROE is +0.12%, compared to LGND's ROE of +0.16%. Regarding short-term risk, BGNE is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check LGND's competition here
BGNE vs CAI Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, CAI has a market cap of 4.9B. Regarding current trading prices, BGNE is priced at $184.71, while CAI trades at $17.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas CAI's P/E ratio is -6.22. In terms of profitability, BGNE's ROE is +0.12%, compared to CAI's ROE of +0.06%. Regarding short-term risk, BGNE is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check CAI's competition here
BGNE vs CGON Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, CGON has a market cap of 4.8B. Regarding current trading prices, BGNE is priced at $184.71, while CGON trades at $54.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas CGON's P/E ratio is -23.47. In terms of profitability, BGNE's ROE is +0.12%, compared to CGON's ROE of -0.23%. Regarding short-term risk, BGNE is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check CGON's competition here
BGNE vs TERN Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, BGNE is priced at $184.71, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas TERN's P/E ratio is -51.41. In terms of profitability, BGNE's ROE is +0.12%, compared to TERN's ROE of -0.20%. Regarding short-term risk, BGNE is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check TERN's competition here
BGNE vs CRSP Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, CRSP has a market cap of 4.8B. Regarding current trading prices, BGNE is priced at $184.71, while CRSP trades at $49.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas CRSP's P/E ratio is -8.01. In terms of profitability, BGNE's ROE is +0.12%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, BGNE is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check CRSP's competition here
BGNE vs MIRM Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, MIRM has a market cap of 4.7B. Regarding current trading prices, BGNE is priced at $184.71, while MIRM trades at $93.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas MIRM's P/E ratio is -6.91. In terms of profitability, BGNE's ROE is +0.12%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, BGNE is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check MIRM's competition here
BGNE vs FOLD Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, BGNE is priced at $184.71, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas FOLD's P/E ratio is -161.00. In terms of profitability, BGNE's ROE is +0.12%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, BGNE is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check FOLD's competition here
BGNE vs SYRE Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, SYRE has a market cap of 4.5B. Regarding current trading prices, BGNE is priced at $184.71, while SYRE trades at $75.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas SYRE's P/E ratio is -35.42. In terms of profitability, BGNE's ROE is +0.12%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, BGNE is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check SYRE's competition here
BGNE vs AKRO Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, BGNE is priced at $184.71, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas AKRO's P/E ratio is -14.57. In terms of profitability, BGNE's ROE is +0.12%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, BGNE is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check AKRO's competition here
BGNE vs ALPN Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, BGNE is priced at $184.71, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas ALPN's P/E ratio is -101.52. In terms of profitability, BGNE's ROE is +0.12%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, BGNE is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check ALPN's competition here
BGNE vs TVTX Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, TVTX has a market cap of 4.3B. Regarding current trading prices, BGNE is priced at $184.71, while TVTX trades at $46.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas TVTX's P/E ratio is -93.48. In terms of profitability, BGNE's ROE is +0.12%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, BGNE is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check TVTX's competition here
BGNE vs CELC Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, CELC has a market cap of 4.3B. Regarding current trading prices, BGNE is priced at $184.71, while CELC trades at $88.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas CELC's P/E ratio is -22.59. In terms of profitability, BGNE's ROE is +0.12%, compared to CELC's ROE of -2.45%. Regarding short-term risk, BGNE is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check CELC's competition here
BGNE vs OPT Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, BGNE is priced at $184.71, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas OPT's P/E ratio is -1.52. In terms of profitability, BGNE's ROE is +0.12%, compared to OPT's ROE of +1.09%. Regarding short-term risk, BGNE is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check OPT's competition here
BGNE vs ERAS Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, ERAS has a market cap of 4.2B. Regarding current trading prices, BGNE is priced at $184.71, while ERAS trades at $13.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas ERAS's P/E ratio is -14.38. In terms of profitability, BGNE's ROE is +0.12%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, BGNE is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ERAS's competition here
BGNE vs MRTX Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, BGNE is priced at $184.71, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas MRTX's P/E ratio is -4.82. In terms of profitability, BGNE's ROE is +0.12%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, BGNE is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check MRTX's competition here
BGNE vs XENE Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, XENE has a market cap of 4.1B. Regarding current trading prices, BGNE is priced at $184.71, while XENE trades at $51.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas XENE's P/E ratio is -10.92. In terms of profitability, BGNE's ROE is +0.12%, compared to XENE's ROE of -0.49%. Regarding short-term risk, BGNE is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check XENE's competition here
BGNE vs MANE Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, MANE has a market cap of 3.9B. Regarding current trading prices, BGNE is priced at $184.71, while MANE trades at $92.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas MANE's P/E ratio is -35.09. In terms of profitability, BGNE's ROE is +0.12%, compared to MANE's ROE of -0.95%. Regarding short-term risk, BGNE is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check MANE's competition here
BGNE vs VCYT Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, VCYT has a market cap of 3.8B. Regarding current trading prices, BGNE is priced at $184.71, while VCYT trades at $48.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas VCYT's P/E ratio is 44.60. In terms of profitability, BGNE's ROE is +0.12%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, BGNE is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check VCYT's competition here
BGNE vs CPRX Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, BGNE is priced at $184.71, while CPRX trades at $31.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas CPRX's P/E ratio is 18.12. In terms of profitability, BGNE's ROE is +0.12%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, BGNE is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check CPRX's competition here
BGNE vs RYZB Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, BGNE is priced at $184.71, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas RYZB's P/E ratio is -57.86. In terms of profitability, BGNE's ROE is +0.12%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, BGNE is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check RYZB's competition here
BGNE vs CBAY Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, BGNE is priced at $184.71, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas CBAY's P/E ratio is -32.81. In terms of profitability, BGNE's ROE is +0.12%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, BGNE is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check CBAY's competition here
BGNE vs KNSA Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, KNSA has a market cap of 3.7B. Regarding current trading prices, BGNE is priced at $184.71, while KNSA trades at $49.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas KNSA's P/E ratio is 54.14. In terms of profitability, BGNE's ROE is +0.12%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, BGNE is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check KNSA's competition here
BGNE vs ACAD Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, ACAD has a market cap of 3.6B. Regarding current trading prices, BGNE is priced at $184.71, while ACAD trades at $21.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas ACAD's P/E ratio is 9.61. In terms of profitability, BGNE's ROE is +0.12%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, BGNE is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ACAD's competition here
BGNE vs CRNX Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, CRNX has a market cap of 3.6B. Regarding current trading prices, BGNE is priced at $184.71, while CRNX trades at $34.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas CRNX's P/E ratio is -6.67. In terms of profitability, BGNE's ROE is +0.12%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, BGNE is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check CRNX's competition here
BGNE vs EWTX Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, EWTX has a market cap of 3.5B. Regarding current trading prices, BGNE is priced at $184.71, while EWTX trades at $32.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas EWTX's P/E ratio is -19.83. In terms of profitability, BGNE's ROE is +0.12%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, BGNE is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check EWTX's competition here
BGNE vs SWTX Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, BGNE is priced at $184.71, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas SWTX's P/E ratio is -13.78. In terms of profitability, BGNE's ROE is +0.12%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, BGNE is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check SWTX's competition here
BGNE vs NAMS Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, NAMS has a market cap of 3.4B. Regarding current trading prices, BGNE is priced at $184.71, while NAMS trades at $29.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas NAMS's P/E ratio is -16.48. In terms of profitability, BGNE's ROE is +0.12%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, BGNE is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check NAMS's competition here
BGNE vs TNGX Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, TNGX has a market cap of 3.3B. Regarding current trading prices, BGNE is priced at $184.71, while TNGX trades at $28.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas TNGX's P/E ratio is -34.55. In terms of profitability, BGNE's ROE is +0.12%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, BGNE is less volatile compared to TNGX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check TNGX's competition here
BGNE vs DNLI Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, DNLI has a market cap of 3.3B. Regarding current trading prices, BGNE is priced at $184.71, while DNLI trades at $20.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas DNLI's P/E ratio is -7.16. In terms of profitability, BGNE's ROE is +0.12%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, BGNE is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check DNLI's competition here
BGNE vs VKTX Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, VKTX has a market cap of 3.2B. Regarding current trading prices, BGNE is priced at $184.71, while VKTX trades at $27.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas VKTX's P/E ratio is -6.69. In terms of profitability, BGNE's ROE is +0.12%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, BGNE is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check VKTX's competition here
BGNE vs TLX Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, TLX has a market cap of 3.2B. Regarding current trading prices, BGNE is priced at $184.71, while TLX trades at $9.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas TLX's P/E ratio is -472.00. In terms of profitability, BGNE's ROE is +0.12%, compared to TLX's ROE of -0.02%. Regarding short-term risk, BGNE is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check TLX's competition here
BGNE vs DNTH Comparison June 2026
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, DNTH has a market cap of 3.2B. Regarding current trading prices, BGNE is priced at $184.71, while DNTH trades at $76.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas DNTH's P/E ratio is -18.07. In terms of profitability, BGNE's ROE is +0.12%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, BGNE is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check DNTH's competition here